Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.32 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.32 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18630157 | 0.91 | BCHE (0.40) | BCHELMNAPOLBSPHK1SPHK2 | |
| SCHEMBL21042965 | 0.85 | LMNA (0.45) | LMNAHSD17B10CYP2C19 | |
| SCHEMBL10205021 | 0.79 | HSD17B10 (0.37) | BCHELMNASMN1; SMN2HSD17B10CYP2C19 | |
| SCHEMBL8235608 | 0.79 | HSD17B10 (0.37) | BCHELMNASMN1; SMN2HSD17B10CYP2C19 | |
| SCHEMBL4898829 | 0.79 | HSD17B10 (0.37) | BCHELMNASMN1; SMN2HSD17B10CYP2C19 | |
| SCHEMBL1074624 | 0.78 | DPP4 (0.38) | LMNASMN1; SMN2HSD17B10CYP2C19 | |
| Hydrochloric Acid SCHEMBL7302950 | 0.78 | HSD17B10 (0.36) | LMNASMN1; SMN2HSD17B10CYP2C19ALDH1A1 | |
| SCHEMBL8197074 | 0.76 | LMNA (0.43) | LMNAHSD17B10CYP2C19 | |
| SCHEMBL4901400 | 0.74 | EPHX1 (0.35) | LMNASMN1; SMN2HSD17B10CYP2C19ALDH1A1 | |
| SCHEMBL5576808 | 0.73 | DPP4 (0.35) | LMNASMN1; SMN2HSD17B10CYP2C19POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170073370-A1 | BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. | 2017-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073370-A1 | BROAD SPECTRUM ANTIBIOTICS | SPAST, NPEPPS, SPOUT1 | BCHE 1198/4885LMNA 1941/4885SMN1; SMN2 601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.